Tritiated D-ala1-peptide T binding: A pharmacologic basis for the design of drugs which inhibit HIV receptor binding
- 1 January 1988
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 15 (4) , 371-379
- https://doi.org/10.1002/ddr.430150404
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptideNature, 1988
- Peptide t sequences prevent neuronal cell death produced by the envelope protein (gp 120) of the human immunodeficiency virusDrug Development Research, 1988
- A strong homology exists between the active T-cell binding gp120 octapeptide of human immunodeficiency virus and the subtilisin cleavage peptide of bovine ribonuclease ABiochemical and Biophysical Research Communications, 1987
- CD4 receptor binding peptides that block HIV infectivity cause human monocyte chemotaxisFEBS Letters, 1987
- PEPTIDE T IN TREATMENT OF AIDSThe Lancet, 1987
- Vasoactive intestinal peptide 1‐12: A ligand for the CD4 (T4)/human immunodeficiency virus receptorJournal of Neuroscience Research, 1987
- Binding of HTLV-III/LAV to T4 + T Cells by a Complex of the 110K Viral Protein and the T4 MoleculeScience, 1986
- Benzodiazepine Receptor-Mediated Chemotaxis of Human MonocytesScience, 1985
- T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAVNature, 1984
- The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirusNature, 1984